Value Proposition
This ex vivo model of the human distal colon reliably mimics and predicts the impact that various food substrates are likely to have on the gut microbiome, which may help food industries better predict the impact of such foods in downstream clinical trials –essentially, improving screening prior to investing in costly animal trials.
This bridges the gap between ex vivo models and real life in vivo physiological situations
Opportunity
We welcome engagement from the following industries;
- Food manufacturers screening test substrates in-house Companies providing such services to food companies
Development Stage
Advantages
Overcomes occasional reliability issue associated with micro-Matrix bioreactor platform as an ex vivo model of the human distal colon.
Tackles the undesirable phenomenon of blooms of one genus or species e.g. E. coli, which can interfere with accurate analysis of the predictive effects of various food substrates on the gut microbiome .
Research Funding:
EI-Food Health Ireland- Fermentates
Marie Curie NEUROFOODS
Teagasc PI: Paul Cotter
